» Articles » PMID: 19660475

Modeling Sequence Evolution in Acute HIV-1 Infection

Abstract

We describe a mathematical model and Monte Carlo (MC) simulation of viral evolution during acute infection. We consider both synchronous and asynchronous processes of viral infection of new target cells. The model enables an assessment of the expected sequence diversity in new HIV-1 infections originating from a single transmitted viral strain, estimation of the most recent common ancestor (MRCA) of the transmitted viral lineage, and estimation of the time to coalesce back to the MRCA. We also calculate the probability of the MRCA being the transmitted virus or an evolved variant. Excluding insertions and deletions, we assume HIV-1 evolves by base substitution without selection pressure during the earliest phase of HIV-1 infection prior to the immune response. Unlike phylogenetic methods that follow a lineage backwards to coalescence, we compare the observed data to a model of the diversification of a viral population forward in time. To illustrate the application of these methods, we provide detailed comparisons of the model and simulations results to 306 envelope sequences obtained from eight newly infected subjects at a single time point. The data from 68 patients were in good agreement with model predictions, and hence compatible with a single-strain infection evolving under no selection pressure. The diversity of the samples from the other two patients was too great to be explained by the model, suggesting multiple HIV-1-strains were transmitted. The model can also be applied to longitudinal patient data to estimate within-host viral evolutionary parameters.

Citing Articles

The Performance of the Current Algorithm of HIV Diagnosis.

Gulmez A, Appak O, Zeka A, Esen N, Sayiner A Iran J Public Health. 2024; 53(7):1569-1577.

PMID: 39086412 PMC: 11287590. DOI: 10.18502/ijph.v53i7.16051.


Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1.

Cassidy T, Stephenson K, Barouch D, Perelson A PLoS Comput Biol. 2024; 20(3):e1011518.

PMID: 38551976 PMC: 11006161. DOI: 10.1371/journal.pcbi.1011518.


Leveraging Donor Populations to Study the Epidemiology and Pathogenesis of Transfusion-Transmitted and Emerging Infectious Diseases.

Bloch E, Busch M, Corash L, Dodd R, Hailu B, Kleinman S Transfus Med Rev. 2023; 37(4):150769.

PMID: 37919210 PMC: 10841704. DOI: 10.1016/j.tmrv.2023.150769.


HIV risk behavior profiles among men who have sex with men interested in donating blood: Findings from the Assessing Donor Variability and New Concepts in Eligibility study.

Custer B, Whitaker B, Pollack L, Buccheri R, Bruhn R, Crowder L Transfusion. 2023; 63(10):1872-1884.

PMID: 37642154 PMC: 11284767. DOI: 10.1111/trf.17515.


Propensity of selecting mutant parasites for the antimalarial drug cabamiquine.

Stadler E, Maiga M, Friedrich L, Thathy V, Demarta-Gatsi C, Dara A Nat Commun. 2023; 14(1):5205.

PMID: 37626093 PMC: 10457284. DOI: 10.1038/s41467-023-40974-8.


References
1.
Fiebig E, Heldebrant C, Smith R, Conrad A, Delwart E, Busch M . Intermittent low-level viremia in very early primary HIV-1 infection. J Acquir Immune Defic Syndr. 2005; 39(2):133-7. View

2.
Chen H, Di Mascio M, Perelson A, Ho D, Zhang L . Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc Natl Acad Sci U S A. 2007; 104(48):19079-84. PMC: 2141911. DOI: 10.1073/pnas.0707449104. View

3.
Keele B, Giorgi E, Salazar-Gonzalez J, Decker J, Pham K, Salazar M . Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2008; 105(21):7552-7. PMC: 2387184. DOI: 10.1073/pnas.0802203105. View

4.
Ribeiro R, Bonhoeffer S . A stochastic model for primary HIV infection: optimal timing of therapy. AIDS. 1999; 13(3):351-7. DOI: 10.1097/00002030-199902250-00007. View

5.
Sagar M, Kirkegaard E, Long E, Celum C, Buchbinder S, Daar E . Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes. J Virol. 2004; 78(13):7279-83. PMC: 421693. DOI: 10.1128/JVI.78.13.7279-7283.2004. View